Pancreatic Neoplasms Clinical Trials

42 recruitingLast updated: June 17, 2026

There are 42 actively recruiting pancreatic neoplasms clinical trials across 18 countries. Studies span Phase 2, Phase 1, Not Applicable, Early Phase 1. Top locations include Shanghai, Shanghai Municipality, China, Manchester, United Kingdom, Milwaukee, Wisconsin, United States. Updated daily from ClinicalTrials.gov.


Pancreatic Neoplasms Trials at a Glance

42 actively recruiting trials for pancreatic neoplasms are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Shanghai, Manchester, and Milwaukee. Lead sponsors running pancreatic neoplasms studies include Nuvance Health, Ruijin Hospital, and Fudan University.

Browse pancreatic neoplasms trials by phase

Treatments under study

About Pancreatic Neoplasms Clinical Trials

Looking for clinical trials for Pancreatic Neoplasms? There are currently 39 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreatic Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreatic Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 42 trials

Recruiting
Phase 1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Ovarian NeoplasmsStomach NeoplasmsLung Neoplasms+5 more
National Cancer Institute (NCI)100 enrolled1 locationNCT06885697
Recruiting

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

Stomach NeoplasmsMesotheliomaPancreatic Neoplasms+3 more
National Cancer Institute (NCI)1,000 enrolled1 locationNCT01950572
Recruiting
Not Applicable

Pancreatic Cancer Screening Using the Enzeavour Assay in Japan

Pancreatic CancerPancreatic Neoplasms
Cosomil, Inc.10,000 enrolled1 locationNCT07605819
Recruiting
Phase 1Phase 2

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckOvarian Neoplasms+8 more
Cancer Research UK167 enrolled4 locationsNCT06380816
Recruiting

Determining Individualized Cancer Therapy in Pancreatic Cancer

Pancreatic Neoplasms
Medical College of Wisconsin1,000 enrolled1 locationNCT05914987
Recruiting
Not Applicable

Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Neoplasms+1 more
ARTIDIS AG200 enrolled1 locationNCT07542041
Recruiting

A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus

Pancreatic CancerDiabetes MellitusPancreatic Neoplasms
Nuvance Health800 enrolled2 locationsNCT03937453
Recruiting

The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer

Pancreatic Ductal AdenocarcinomaPancreatic Cancer Stage IVPancreatic Neoplasms+1 more
Nuvance Health200 enrolled1 locationNCT04406831
Recruiting

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

Pancreatic Neoplasms
Nuvance Health200 enrolled1 locationNCT03250078
Recruiting
Not Applicable

Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia

Pancreatic NeoplasmsPancreatoduodenectomyHypotension
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran206 enrolled1 locationNCT06953193
Recruiting
Phase 2

Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases

Pancreatic NeoplasmsHepatic Metastasis of Pancreatic Cancer
Ruijin Hospital50 enrolled1 locationNCT07504471
Recruiting

Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors

Pancreatic Neuroendocrine TumorSolid Pancreatic Neoplasms
Fudan University1,000 enrolled2 locationsNCT05847855
Recruiting
Not Applicable

EUS-guided RFA for Pancreatic Neoplasms

Pancreatic Neoplasms
Chinese University of Hong Kong30 enrolled1 locationNCT03218345
Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Breast CancerLiver CancerEsophageal Cancer+35 more
UMC Utrecht8,000 enrolled18 locationsNCT04075305
Recruiting

Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts

Pancreas CancerPancreatic Neoplasms
Johns Hopkins University5,000 enrolled1 locationNCT04473794
Recruiting

68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors

Breast Neoplasms、Lung Neoplasms、Pancreatic Neoplasms
Peking University First Hospital10 enrolled1 locationNCT07331532
Recruiting
Phase 2

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic NeoplasmsCancer of Pancreas+4 more
UNC Lineberger Comprehensive Cancer Center45 enrolled1 locationNCT03977233
Recruiting
Phase 1Phase 2

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Pancreatic CancerAdvanced CancerPancreatic Ductal Adenocarcinoma+1 more
Changhai Hospital30 enrolled1 locationNCT04146298
Recruiting

Pancreatic Cancer Detection Consortium

Pancreatic CancerPancreatic CarcinomaPancreatic Ductal Adenocarcinoma+10 more
City of Hope Medical Center2,000 enrolled11 locationsNCT06388967
Recruiting
Phase 1Phase 2

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Carcinoma, Non-Small Cell LungOvarian NeoplasmsColorectal Neoplasms+3 more
Eli Lilly and Company540 enrolled49 locationsNCT04956640